公开(公告)号：US20050014821A1

公开(公告)日：2005-01-20

申请号：US10625986

申请日：2003-07-24

申请人： Li-Huei Tsai ,  Ming-Sum Lee ,  Jonathan Cruz

发明人： Li-Huei Tsai ,  Ming-Sum Lee ,  Jonathan Cruz

IPC分类号： A01K67/027 ,  A61K31/00 ,  A61K31/365 ,  A61K49/00 ,  C12N15/85 ,  C12Q1/48 ,  G01N33/68

CPC分类号： A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0318 ,  A61K31/00 ,  A61K31/365 ,  A61K49/0008 ,  C07K2319/41 ,  C07K2319/60 ,  C12N15/8509 ,  C12N2710/16611 ,  C12N2710/16643 ,  C12N2830/00 ,  C12Q1/485 ,  G01N33/6896 ,  G01N2500/04 ,  G01N2800/2821

摘要： Disclosed are improved methods of treating individuals with Alzheimer's disease (AD) as well as methods to diagnose AD in an individual. Also included are compounds and methods of identifying compounds to treat AD. The present invention also discloses methods for decreasing the phosphorylation of amyloid precursor protein (APP), including inhibiting phosphorylation of amino acid residue tyrosine 668 of APP and for reducing cleavage of APP. The present invention further discloses transgenic (Tg), non-human animals and cells expressing a p25 transgene that are models of neurodegenerative diseases. Embodiments of the present invention are directed to methods wherein the Tg animals and Tg cells of the invention are used to screen for modulators of neurodegenerative disorders. The Tg animals and cells of the present invention are useful for elucidating the mechanisms of neurodegenerative disorders.

摘要翻译： 公开了治疗患有阿尔茨海默病（AD）的个体的改进方法以及在个体中诊断AD的方法。 还包括鉴定化合物以治疗AD的化合物和方法。 本发明还公开了降低淀粉样蛋白前体蛋白（APP）的磷酸化的方法，包括抑制APP的氨基酸残基酪氨酸668的磷酸化和减少APP的切割。 本发明还公开了转基因（Tg）非人动物和表达作为神经变性疾病模型的p25转基因的细胞。 本发明的实施方案涉及其中本发明的Tg动物和Tg细胞用于筛选神经变性疾病的调节剂的方法。 本发明的Tg动物和细胞可用于阐明神经变性疾病的机制。

公开(公告)号：US07250551B2

公开(公告)日：2007-07-31

申请号：US10625986

申请日：2003-07-24

申请人： Li-Huei Tsai ,  Ming-Sum Lee ,  Jonathan C. Cruz

发明人： Li-Huei Tsai ,  Ming-Sum Lee ,  Jonathan C. Cruz

IPC分类号： A01K67/27 ,  G01N33/00 ,  C12N15/00 ,  C12N5/00

CPC分类号： A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0318 ,  A61K31/00 ,  A61K31/365 ,  A61K49/0008 ,  C07K2319/41 ,  C07K2319/60 ,  C12N15/8509 ,  C12N2710/16611 ,  C12N2710/16643 ,  C12N2830/00 ,  C12Q1/485 ,  G01N33/6896 ,  G01N2500/04 ,  G01N2800/2821

摘要： Disclosed are improved methods of treating individuals with Alzheimer's disease (AD) as well as methods to diagnose AD in an individual. Also included are compounds and methods of identifying compounds to treat AD. The present invention also discloses methods for decreasing the phosphorylation of amyloid precursor protein (APP), including inhibiting phosphorylation of amino acid residue tyrosine 668 of APP and for reducing cleavage of APP. The present invention further discloses transgenic (Tg), non-human animals and cells expressing a p25 transgene that are models of neurodegenerative diseases. Embodiments of the present invention are directed to methods wherein the Tg animals and Tg cells of the invention are used to screen for modulators of neurodegenerative disorders. The Tg animals and cells of the present invention are useful for elucidating the mechanisms of neurodegenerative disorders.

摘要翻译： 公开了治疗患有阿尔茨海默病（AD）的个体的改进方法以及在个体中诊断AD的方法。 还包括鉴定化合物以治疗AD的化合物和方法。 本发明还公开了降低淀粉样蛋白前体蛋白（APP）的磷酸化的方法，包括抑制APP的氨基酸残基酪氨酸668的磷酸化和减少APP的切割。 本发明还公开了转基因（Tg）非人动物和表达作为神经变性疾病模型的p25转基因的细胞。 本发明的实施方案涉及其中本发明的Tg动物和Tg细胞用于筛选神经变性疾病的调节剂的方法。 本发明的Tg动物和细胞可用于阐明神经变性疾病的机制。